Central Asian Journal of Medicine


Aim of the study: the prevalence of benign prostate hyperplasia and the importance of risk factors in the development of pathology among the unorganized male population in Andijan was analyzed. Materials and methods: the total volume of the competition was 2702 people, and the survey coverage was 1977 people (72.3%). Conclusions: benign prostatic hyperplasia was registered in 844 (42.7%) people, the lowest rate was in the age group 30-39 years old, and the highest in the age group 50-59 years old (28.4%). The results of the assessment of the main risk factors for the development of prostatic hyperplasia showed that 77.1% of the respondents smoked, 87.8% of the respondents drank alcohol, 82.5% of the respondents took drugs often or too much. Eating disorders were found in 60.2% of the respondents, 52.7% of the respondents consumed fresh vegetables and fruits below the recommended norms, 59.1% of the respondents consumed salt more than the recommended norms.

First Page


Last Page



1. Gorilovskiy L.M., Zingerenko M.B. Dobrokachestvennaya hyperplasia predstatelnoy jelezi // Lechashiy vrach. - 2003. - №7. - ttps://www.lvrach.ru/2003/07/4530505. 2. Voshchula V.I., Pranovich A.A., Shchaveleva M.V. Epidemiologicheskie aspekti zabolevaemosti dobrokachestvennoy giperplaziei predstatelnoy jelezi v Respublike Belarus // Voprosy organizatsii i informatizatsii zdravooxraneniya.-2010.-№1.-p.42-47. 3. Kaprin A.D., Apolixin O.I., Sivkov A.V. y dr. Analyz uronefrologicheskoy zabolevaemosti I smertnosti v Rossiyskoy Federatsii za period 2002-2014 gg. Po dannim ofitsialnoy statistiki // Eksperimentalnaya i klinicheskaya urologiya. - 2011. - №3. - p. 4-16. 4. Korneev I.A. Rossiyskiy opit primeneniya suppozitoriev Vitaprost forte u bolnyx s symptomami nijnix mochevyx putey i dobrokachestvennoy giperplaziey predstatelnoy jelezy: sravnitelnyy analiz issledovaniy // Urologiya. - 2017. - №3. - p. 140. 5. Konoplya A.I., Shestakov S.G. Adenoma of the prostate gland, complicated by chronic prostatitis: Monograph for doctors, high school students and trainee urologists. - Kursk, -2006. - p.219 6. Pushkar D.Yu., Rasner P.I. Symptomy nijnix mochevivodyashix putey i dobrokachestvennaya gyperplazia predstatelnoy jelezi // Urologiya. - 2006. - №3. - S. 4-18. 7. Sannikov P.G., Kuznetsov P.B., Styajkina S.N. et al. Benign hyperplasia of the prostate gland. Description of the clinical case // European journal of biomedicine and life science. - 2015. - №2. - p. 40 - 45 8. Sevryukov F.A., Kamaev I.A., Grib M.N. and dr. Risk factors and quality of life of patients with benign prostatic hyperplasia // Rossiyskiy mediko-biologicheskiy vestnik imeni akademika I.P. Pavlova. - St. Petersburg, 2011. - Volume 19. - №3. - p. 48-52. 9. Andersson K.E., Chappie C.R., Hofner K. Future drugs for the treatment of benign prostatic hyperplasia // World J. Urol. - 2002. - Vol. 19. - №6. - P. 436-442. 10. Carnevale F. C., Antunes A. A., da Motta Leal Filho J. M. et al. Prostatic artery embolization as a primary treatment for benign prostatic hyperplasia: preliminary results in two patients // CardioVascular and Interventional Radiology. - 2010. - Vol. 33. - №2. - P. 355–361. 11. Verhamme K.M. et al. Treatment strategies, patterns of drug use and treatment discontinuation in men with LUTS suggestive of benign prostatic hyperplasia: the Triumph project // Eur. Urol. - 2003. - Vol. 44. - №5. - P. 539-545. 12. Miller D.C., Saigal C.S., Litwin M.S. The demographic burden of urologic diseases in America // Urol. Clin. North. Am.- 2009.-Vol.36.- №1.-P.11-27



To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.